Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/jcmm.13136

http://scihub22266oqcxt.onion/10.1111/jcmm.13136
suck pdf from google scholar
C5571536!5571536 !28272773
unlimited free pdf from europmc28272773
    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid28272773
      J+Cell+Mol+Med 2017 ; 21 (9 ): 2140-2152
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease #MMPMID28272773
  • Hinder LM ; Park M ; Rumora AE ; Hur J ; Eichinger F ; Pennathur S ; Kretzler M ; Brosius FC 3rd ; Feldman EL
  • J Cell Mol Med 2017[Sep]; 21 (9 ): 2140-2152 PMID28272773 show ga
  • Treating insulin resistance with pioglitazone normalizes renal function and improves small nerve fibre function and architecture; however, it does not affect large myelinated nerve fibre function in mouse models of type 2 diabetes (T2DM), indicating that pioglitazone affects the body in a tissue-specific manner. To identify distinct molecular pathways regulating diabetic peripheral neuropathy (DPN) and nephropathy (DN), as well those affected by pioglitazone, we assessed DPN and DN gene transcript expression in control and diabetic mice with or without pioglitazone treatment. Differential expression analysis and self-organizing maps were then used in parallel to analyse transcriptome data. Differential expression analysis showed that gene expression promoting cell death and the inflammatory response was reversed in the kidney glomeruli but unchanged or exacerbated in sciatic nerve by pioglitazone. Self-organizing map analysis revealed that mitochondrial dysfunction was normalized in kidney and nerve by treatment; however, conserved pathways were opposite in their directionality of regulation. Collectively, our data suggest inflammation may drive large fibre dysfunction, while mitochondrial dysfunction may drive small fibre dysfunction in T2DM. Moreover, targeting both of these pathways is likely to improve DN. This study supports growing evidence that systemic metabolic changes in T2DM are associated with distinct tissue-specific metabolic reprogramming in kidney and nerve and that these changes play a critical role in DN and small fibre DPN pathogenesis. These data also highlight the potential dangers of a 'one size fits all' approach to T2DM therapeutics, as the same drug may simultaneously alleviate one complication while exacerbating another.
  • |*Gene Expression Profiling [MESH]
  • |*Metabolic Networks and Pathways/genetics [MESH]
  • |*Sequence Analysis, RNA [MESH]
  • |Animals [MESH]
  • |Computational Biology [MESH]
  • |Diabetic Nephropathies/*genetics/*metabolism [MESH]
  • |Diabetic Neuropathies/*genetics/*metabolism [MESH]
  • |Kidney Glomerulus/drug effects/pathology [MESH]
  • |Male [MESH]
  • |Mice, Inbred C57BL [MESH]
  • |Nerve Fibers/drug effects/pathology [MESH]
  • |Organ Specificity/genetics [MESH]
  • |Pioglitazone [MESH]
  • |RNA, Messenger/genetics/metabolism [MESH]
  • |Reproducibility of Results [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box